Drug Database
CO

cobicistat + darunavir (G006 / Rezolsta / Prezcobix)

✓ Approved

Johnson & Johnson Services, Inc. · CYP3A4 · 小分子

什么是 cobicistat + darunavir?

cobicistat + darunavir 是一种小分子,由Johnson & Johnson Services, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名G006, Rezolsta, Prezcobix
公司Johnson & Johnson Services, Inc.
药物类别小分子
分子靶点CYP3A4,
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

cobicistat + darunavir 作用于 2 个分子靶点:

CYP3A4cytochrome P450 family 3 subfamily A member 4 (CP33, HLP)
gag-pol, HIV-1 (gag-pol)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

cobicistat + darunavir 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsAcquired immunodeficiency syndrome✓ Approved

相关研究文献

PubMedBritish journal of clinical pharmacology2026-11-18

Initiation of lenacapavir with dose escalation in a patient receiving rifabutin: A case report with therapeutic drug monitoring.

McIntyre Mark M, Tseng Alice A, Cheung Alexandra A, Leung Felix F et al.

Lenacapavir is a first-in-class HIV-1 capsid inhibitor with long-acting pharmacokinetics that enable 6-monthly subcutaneous dosing after initiation with oral lead-in. Lenacapavir is a CYP3A4, UGT1A1 and P-gp substrate; inducers of these enzymes and P-gp can significantly decrease lenacapavir concentrations. In patients receiving lenacapavir for HIV pre-exposure prophylaxis (PrEP), supplemental lenacapavir doses can be administered if rifabutin (moderate inducer) or rifampin (potent inducer) are initiated. However, these recommendations have not been extended to lenacapavir when used for HIV treatment, and little is known about initiating lenacapavir in patients on stable therapy with inducers. We describe a 30-year-old man with advanced HIV infection and disseminated Mycobacterium avium complex infection receiving rifabutin and concurrent darunavir/ritonavir in whom lenacapavir was initiated with a 50% increase in both oral (900 mg on Days 1 and 2) and subcutaneous loading doses (1390.5 mg on Day 1). Therapeutic drug monitoring using validated UPLC-MS/MS method demonstrated that lenacapavir plasma concentrations remained above the target of 15.5 ng/mL (4× protein-adjusted 95% effective concentration [PA-EC95]) over the dosing interval, with Cmax of 245.7 ng/mL and a projected Cmin of 19.5 ng/mL at 6 months. HIV viral load remained suppressed. This case demonstrates that dose-adjusted lenacapavir can achieve therapeutic exposures in the presence of pre-existing moderate induction. These findings provide clinically relevant pharmacological insight to support the use of lenacapavir in complex patients requiring rifamycin therapy.

PMID 43051964
阅读全文 →
PubMedScientific reports2026-11-12

Distal amino-acid substitutions contribute to HIV protease inhibitor resistance as directly as proximal amino-acid substitutions.

Das Debananda D, Hayashi Hironori H, Takamatsu Yuki Y, Aoki Manabu M et al.

There are two categories of drug-resistance-associated amino-acid substitutions responsible for causing drug resistance in HIV-1 protease: (i) major and (ii) minor substitutions. In general, major substitutions mostly arise early during treatment, reduce susceptibility to the drug and are mostly proximal to the protease active site. Minor substitutions mostly arise later, may provide incremental resistance and/or improve viral fitness and are often distal from the active site. However, no precise definitions of such two categories exist. Herein, using X-ray crystallography and molecular dynamics (MD) simulations we examined the structural basis of antiviral resistance of HIVDRV R p51, an HIV-1 variant that has three proximal (V32I, V82I, I84V) and eleven distal substitutions (L10I/I15V/K20R/L24I/L33F/M36I/ M46L/ I54M/L63P/K70Q/L89M) in the protease region (PRp51), and has high resistance against a protease inhibitor darunavir (DRV), but not against another protease inhibitor GRL142. MD demonstrated that the proximal and distal substitutions work in concert to carry out structural changes that result in larger perturbations in inter-residue distances and active site cavity volume for DRV-PRp51 over DRV-PRwt compared to GRL142-PRp51 over GRL142-PRwt. These results provided a rationale for the different resistance profiles of DRV and GRL142. The results also suggest reconsideration of the simplistic classification of substitutions as either major or minor. The online version contains supplementary material available at https://doi.org/10.1038/s41598-026-64620-7.

PMID 43019068
阅读全文 →
PubMedBiochemistry2026-11-03

Beyond the Active Site: Allosteric Tail of HIV-1 Protease Is a Potential Target for Inhibiting Dimerization.

Dakshinamoorthy Avinash A, Senapati Sanjib S

HIV protease (HIVPR) is one of the key targets in AIDS therapy. All ten FDA-approved drugs targeting this enzyme compete with the substrates in binding to its active site. However, the emergence of drug-resistant mutants in active and nonactive sites of HIVPR has compromised the efficacy of these drugs. Nonetheless, darunavir (DRV) and tipranavir (TPV) have exhibited greater success than the other eight drugs, presumably due to their dual mode of action: (i) inhibiting protease activity and (ii) blocking protease dimerization. Although crystal structures have explained the inhibitory mechanism of protease activity, the mechanism of inhibiting the dimerization process is poorly understood. In this study, we employ advanced molecular dynamics simulation methods to identify the precise binding motifs of DRV and TPV with monomeric HIVPR. Our results suggest that both inhibitors bind stably to an allosteric pocket located in the tail region of the enzyme. Results also elucidate reversible association-dissociation of the drugs between the conventional active site and the newly identified tail cavity through surface diffusion. Structural analysis revealed that drug binding to the tail pocket induces a conformational extension of the C-terminal α-helix, a change that sequesters the terminal residues required for stable dimer formation. Our finding aligns very well with the reported ESI-MS spectra showing the tail interface as a crucial domain in forming a stable HIV protease dimer. Our result paves the way for designing a new class of HIVPR drugs that could target the C-terminal to effectively lock it in the monomeric form, potentially bypassing the cross-resistance due to active-site mutations.

PMID 42975164
阅读全文 →
PubMedJournal of pharmacy practice2026-10-26

Dose-Reduced Apixaban for Thromboembolism in a Patient With Obesity on Cobicistat: A Case Report.

Womble Katlyn K, Mize Marcus M, Baker Carrie C, Bowers Riley R

Background/Objective: Current guidelines recommend a 50% dose reduction of apixaban for patients receiving strong CYP3A4/P-glycoprotein (P-gp) inhibitors regardless of body habitus. However, evidence supporting this dose adjustment in patients with severe obesity (BMI >40 kg/m2) is limited. This report describes the use of dose-reduced apixaban for the treatment of venous thromboembolism in a patient with a BMI >50 kg/m2 receiving a strong CYP3A4/P-gp inhibitor. Summary: A 38-year-old female with a BMI of 81.71 kg/m2 and a history of HIV on a cobicistat-containing antiretroviral regimen was diagnosed with a left femoral deep vein thromboembolism. She was initially treated with warfarin and enoxaparin bridge therapy but was transitioned to apixaban prior to discharge. Apixaban was initiated at a 50% dose reduction due to the concomitant use of cobicistat, a strong CYP3A4/P-gp inhibitor. The patient successfully completed therapy without recurrence of thromboembolism or bleeding complications. Conclusion: This case demonstrates the successful use of dose-reduced apixaban in a patient with a BMI >50 kg/m2 receiving a CYP3A4/P-gp inhibitor for the treatment of venous thromboembolism and adds to available literature on apixaban dosing in patients with obesity.

PMID 42933124
阅读全文 →
PubMedAntiviral research2026-10-26

WG-am combinations restore antiviral potency against fostemsavir and lenacapavir-resistant HIV-1.

Giammarino Federica F, van de Klundert Maarten Aa MA, Saladini Francesco F, Zazzi Maurizio M et al.

Resistance to fostemsavir (FTR) and lenacapavir (LEN) poses critical challenges for heavily treatment-experienced (HTE) people with HIV-1 who have exhausted conventional therapeutic options. We evaluated the antiviral synergy of tryptophylglycine-amide (WG-am), a naturally occurring dipeptide from HIV-1 elite controllers that inhibits viral entry and reverse transcription, in combination with seven antiretrovirals against FTR- and LEN-resistant HIV-1 viruses. Combination assays were performed in TZM-bl cells using a 7×7 dose-matrix format against nine HIV-1 viruses with defined FTR- or LEN-resistance mutations. Synergy was quantified using the zero-interaction potency (ZIP) model in SynergyFinder across all concentrations and at the ≥90% viral inhibition threshold. Three priority combinations - with ibalizumab (IBA), darunavir (DRV), and FTR - were validated in activated PBMCs from three independent donors. WG-am demonstrated synergistic or additive interactions with all seven antiretrovirals; no antagonism was detected. IBA and DRV showed the highest and most consistent synergy across both resistance backgrounds. FTR showed paradoxical synergy against FTR-resistant virus (peak ZIP 15.58 against S375T). At the ≥90% inhibition threshold, 87.3% (55/63) of combination pairs were synergistic. PBMC validation confirmed synergy for all six priority combinations (ZIP 11.01-17.19), with WG-am + FTR scores exceeding TZM-bl values in primary cells. WG-am-based combinations demonstrate synergistic antiviral activity against FTR- and LEN-resistant HIV-1 in reporter cells and primary immune cells. IBA, DRV, and FTR are identified as priority combination partners for WG-am as a component of resistance-informed salvage regimens for HTE patients with limited treatment options.

PMID 42933201
阅读全文 →
PubMedJournal of chemical theory and computation2026-10-23

Coupling Quantum Mechanical Modeling and Molecular Dynamics on Heterogeneous Supercomputers for Studying Distal Mutation Effects on Drug Binding in HIV-1.

Dawson William W, Beal Louis L, Zaccaria Marco M, Genovese Luigi L

Predicting how protein mutations affect drug binding remains a major challenge, particularly when the mutations are distal from the binding site. In this study, we introduce a coupled simulation workflow that combines classical molecular dynamics (MD) with high-throughput quantum mechanical (QM) analysis to reveal the electronic structure signatures of mutation-induced drug resistance in the HIV-1 protease. Our workflow leverages GPU-accelerated MD to generate conformational ensembles, and performs in operando linear-scaling density functional theory (DFT) calculations on selected frames parallelized on a coupled partition of CPU nodes. This design enables efficient, massively parallel quantum analysis of protein-ligand complexes at atomic resolution. Using this approach, we investigate resistance to the antiviral Darunavir in a multimutant HIV-1 protease variant. By mapping the network of electronic interactions across the binding interface, our results highlight the critical role of conformational sampling and quantum insight in understanding distal mutation effects, and demonstrate a scalable computational strategy for studying complex biophysical mechanisms of drug resistance. We argue that this type of analysis may pave the way for designing inhibitors that maintain binding stability against systemic, mutation-induced destabilization.

PMID 42917266
阅读全文 →

注册免费账户还可查看另外 2562 篇文献

免费注册查看全部文献 →

了解更多cobicistat + darunavir